Home Healthcare IT Women’s Health Care Market Size, Trends and Growth Analysis Report 2031

Women’s Health Care Market

Women’s Health Care Market Size, Share & Trends Analysis Report By Drug (Prolia, Premarin, Mirena, Forteo, NuvaRing, Lo Loestrin Fe, Makena, Vagifem, Lupron, Yasmin, Others), By Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome, Other application, Infertility, Reproductive health Manegment, Genecologic Cancer, Others), By Diagnosis (Bone Densitometry, Diagnostic Imaging Tests, Biopsies, Ovulation Testing, Others), By Treatment (Therapeutics, Surgeries, Others), By End User (Hospitals & Clinics, Gynecology Centers, Research Institutes, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI1294DR
Study Period 2019-2031 CAGR 14%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD XX Billion
Forecast Year 2031 Forecast Year Market Size USD 2450 Million
Largest Market North America Fastest Growing Market
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global women's health care market size is poised for remarkable growth, with a projected CAGR of 14% during the forecast period from 2023 to 2031. This robust expansion is expected to propel the women's health care market to USD 2450 million by 2031. As per the WHO, the number of women age 60 and over will increase from about 336 million in 2000 to over 1 billion in 2050. Many of the biggest healthcare companies in the country, including Centene, Elevance Health, and CVS, are now led by women. Women have 25% of leadership positions in the global healthcare industry, according to the WHO, even though they only make up 10% of C-suite positions at Fortune 500 companies. These figures are hardly shocking, as women make up about 70% of the healthcare workforce. According to the National Osteoporosis Foundation, of the estimated 10 million Americans with osteoporosis, about eight million, or 80%, are women.

Women go through certain unique health care challenges and are more likely to be diagnosed with certain diseases than men. The leading causes of death among women are chronic diseases and conditions such as cardiovascular diseases (CVD), cancer, and diabetes. Therefore, there is a high demand for women’s healthcare. 

Market Dynamics

Growing Number of Aging Women across Globe

Aging women make up a significant proportion of the world's population, with constant growth in number across the globe. Women outnumber men in older age groups, and this imbalance increases with age. There are a variety of “determinants” that surround individuals, families, and nations to determine a person’s active aging. These determinants affect well-being directly or indirectly.

The determinants of active aging are interconnected in many ways, and the relationship between them is important. For example, poor women (economic determinant) are more likely to be exposed to inadequate housing (physical determinant), societal violence (social determinant), and not eat nutritious foods (behavioral determinant). Therefore, increasing the risks for women’s health and, thus, boosting women's health care market growth

Figure 1: Determinants of Active Aging


Source: Active Aging: A Policy Framework, WHO, 2002 (www.who.int).

Increasing Chronic Illness in Women Impacts market growth positively.

The three leading causes of death in older women are heart disease, cancer, and stroke. Heart disease is the leading cause of death in women over 60. Most women in the age group of 75 through 85 are more prone to osteoporosis. According to the National Osteoporosis Foundation, across the globe, osteoporosis affects more than 8 million women over the age of 50. The risk of osteoporosis increases in women during the post-menopause period and causes 2 million fractures for USD 19 billion annually, and costs will rise as the population ages.

Moreover, about one in five women over the age of 65 is affected by some type of cancer. Cancer is the second-leading cause of death for senior women. Most of the newly diagnosed breast cancer cases are in women over the age of 60, while the incidence of ovarian cancer peaks when women are in their 70s. Furthermore, stroke is the third-leading cause of death for American women. The Centers for Disease Control and Prevention estimate that one in five American women suffers from stroke, and more than half of women who have a stroke die from the event.

Also, diabetes, the seventh leading cause of death in the United States, can lead to serious and costly complications, including heart disease, stroke, amputations, blindness, and kidney disease. Women with diabetes have a higher risk of heart disease, blindness, and depression than men do. Alzheimer's disease in women is twice as likely to occur in men.

Depression affects twice as many senior women as men, most commonly between ages 40 and 59. Arthritis affects more than half of all seniors over the age of 65, and women are more prone to it than men. Obesity is a major concern, affecting nearly 41 percent of women between the ages of 65 and 74, putting them at risk for several diseases. thus contributing to the growth of the women’s healthcare market.

Growing Demand for Contraceptives to Prevent Unintended Pregnancies Contributing to Market Growth

According to the WHO, in 2016, in developing countries such as Asia, Africa, and South America, there were around 21 million pregnancies among adolescent girls aged 15–19 years. An estimated 23 million adolescent girls have an unmet need for modern contraception and are at risk of unintended pregnancy. Considerable gaps persist in the use of modern methods among couples who want to prevent pregnancy.

In 2015–2017, 64.9% of the 72.2 million women aged 15–49 in the United States were using contraception to avoid unintended pregnancies. Growth in contraceptive demand until 2030 is expected mainly in the regions of sub-Saharan Africa and Oceania. Between 2015 and 2030, contraceptive use is projected to grow, particularly in regions where less than half of married or in-union women of reproductive age currently use contraception. thus boosting market growth.

Regional Analysis

North America to Dominate the Women’s Health Care Market during the Forecast Period

North America dominates the market for women’s health care as the region is supported by the increasing aging women population, the growing prevalence of diseases like postmenopausal osteoporosis, the increasing median age of first-time pregnancies, and increased healthcare spending in the US and Canada. 

Estrogen, a hormone in women that protects bones, decreases sharply when women reach menopause, which can cause bone loss. Therefore, the chance of developing osteoporosis increases as women reach menopause. Also, the high awareness and understanding regarding the use of contraceptives and sex education among women and the easy access to modern contraception as compared to developing countries propel market growth in this region. Besides, the local presence of key players, high disposable income, and lifestyle changes accelerate regional market growth.

Report Scope

Report Metric Details
By Drug
  1. Prolia
  2. Premarin
  3. Mirena
  4. Forteo
  5. NuvaRing
  6. Lo Loestrin Fe
  7. Makena
  8. Vagifem
  9. Lupron
  10. Yasmin
  11. Others
By Application
  1. Hormonal Infertility
  2. Postmenopausal Osteoporosis
  3. Endometriosis
  4. Contraceptives
  5. Menopause
  6. Polycystic Ovary Syndrome
  7. Other application
  8. Infertility
  9. Reproductive health Manegment
  10. Genecologic Cancer
  11. Others
By Diagnosis
  1. Bone Densitometry
  2. Diagnostic Imaging Tests
  3. Biopsies
  4. Ovulation Testing
  5. Others
By Treatment
  1. Therapeutics
  2. Surgeries
  3. Others
By End User
  1. Hospitals & Clinics
  2. Gynecology Centers
  3. Research Institutes
  4. Others
Company Profiles Amgen Inc. (US) Pfizer Inc. (US) Bayer AG (Germany) Merck & Co. (US) Allergan (Dublin) Eli Lilly And Company (US) AMAG Pharmaceuticals (US) Novo Nordisk A/S (Denmark) AbbVie Inc. (US) Johnson & Johnson (US)
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

Prolia Drug Segment to Dominate the Market during the Forecast Period

Based on the drug, the global women’s health care market is majorly segmented into Prolia, Premarin, Mirena, Forteo, NuvaRing, Lo Loestrin Fe, Makena, Vagifem, Lupron, Yasmin, and others. The Prolia drug segment accounted for the largest women’s health care market share. Prolia is a prescription treatment used for treating postmenopausal osteoporosis in people who are at high risk for fractures or weakness in the bones. This medication works by decelerating bone loss to better maintain strong bones and reduce the risk of broken bones (fractures).

Denosumab belongs to monoclonal antibodies, a class of drugs used to prevent certain cells in the body called osteoclasts from breaking down bones. The large share of this segment can be attributed to the rising aging women population. Thus, the increase in women falling under the risk category of menopause is contributing to the upsurge in demand for Prolia.

Market Size By Drug

Market Size By Drug
  • Prolia
  • Premarin
  • Mirena
  • Forteo
  • NuvaRing
  • Lo Loestrin Fe
  • Makena
  • Vagifem
  • Lupron
  • Yasmin
  • Others
  • Recent Developments

    Digitalization of women’s health through the platform of Femtech, motivating women to access and use applications for managing health issues Femtech continues to serve the purpose of addressing the health and wellness needs of women through software, diagnostics, products, and tech-enabled health services.

    Top Key Players

    Women’s Health Care Market Share of Key Players

    Women’s Health Care Market Share of Key Players
    Amgen Inc. (US) Pfizer Inc. (US) Bayer AG (Germany) Merck & Co. (US) Allergan (Dublin) Eli Lilly And Company (US) AMAG Pharmaceuticals (US) Novo Nordisk A/S (Denmark) AbbVie Inc. (US) Johnson & Johnson (US) Others

    Frequently Asked Questions (FAQs)

    What is the projected growth rate of the global women's health care market, and what factors contribute to this growth?
    The women's health care market is projected to grow at a CAGR of 14.0% during the forecast period. The key contributing factors include the increasing number of aging women worldwide, the rise in chronic illnesses impacting women, and a growing demand for contraceptives to prevent unintended pregnancies.
    The report covers North America, Europe, APAC, Middle East and Africa, and LATAM. North America is expected to dominate due to factors such as a rising aging women population, prevalence of diseases like postmenopausal osteoporosis, increased median age of first-time pregnancies, and higher healthcare spending in the US and Canada.
    The leading causes of death among women include cardiovascular diseases, cancer, and diabetes. The prevalence of these chronic conditions in aging women positively impacts the women's healthcare market by creating a high demand for healthcare services and treatments.
    The Prolia drug segment dominates the market, particularly due to its effectiveness in treating postmenopausal osteoporosis in individuals at high risk for fractures. The rise in the aging women population contributes to the increased demand for Prolia.
    Femtech, through digitalization, addresses the health and wellness needs of women by providing software, diagnostics, products, and tech-enabled health services. This trend contributes to recent developments in the women's healthcare market by encouraging women to access and use applications for managing health issues.

    We are featured on :